Effectiveness and safety of switching to biosimilar infliximab and etanercept in patients with psoriasis

Dermatol Ther. 2019 May;32(3):e12846. doi: 10.1111/dth.12846. Epub 2019 Feb 22.

Authors

Tamara Lund¹, Carsten Sand¹, Robert Gniadecki¹, Simon F Thomsen^{1

2}

Affiliations

¹ Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark.
² Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark.

PMID: 30697879
DOI: 10.1111/dth.12846

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Antirheumatic Agents / administration & dosage
Antirheumatic Agents / adverse effects
Biosimilar Pharmaceuticals / administration & dosage*
Biosimilar Pharmaceuticals / adverse effects
Etanercept / administration & dosage*
Etanercept / adverse effects
Female
Humans
Infliximab / administration & dosage*
Infliximab / adverse effects
Male
Middle Aged
Psoriasis / drug therapy*
Retrospective Studies
Treatment Outcome

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Infliximab
Etanercept